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1. Introduction
Clinical studies suggest that repeated intermittent exposure to 
dopamine agonists or releasers such as amphetamine and co-
caine and non-competitive NMDA receptor antagonists such as 
ketamine and phencyclidine (PCP) can induce psychotic symp-
toms very similar to those observed in patients with schizophre-
nia (Bell, 1965; Janowsky and Risch, 1979; Javitt and Zukin, 1991). 
These drug-induced symptoms often emerge gradually and are 
progressively worsened with repeated drug exposure over a period 
of time (Ellinwood et al., 1973; Griffith et al., 1972). They are most 
often observed following a chronic escalating pattern of drug ex-
posure (Angrist, 1994; Simon et al., 2002). This temporal feature 
is often modeled in animals by repeatedly treating them with psy-
chotomimetic drugs and then examining the progressive increase 
in the sensitivity of an animal’s response to the psychotogenic 
properties of drugs (Martinez et al., 2005; Nestler, 2001; Robinson 
and Becker, 1986), most noticeably, behavioral sensitization in the 
forms of locomotor activity and stereotypy (Segal et al., 1981; Segal 
and Mandell, 1974).
One issue with psychomotor sensitization and stereotypy as 
behavioral indices of schizophrenic symptoms is that they are not 
essential features of schizophrenia and do not seem to capture the 
emotional, cognitive, and perceptual disturbances that character-
ize schizophrenic disorders. Other behavioral abnormalities in-
duced by repeated psychotomimetic drug treatment, such as dis-
ruption of prepulse inhibition (PPI) of acoustic startle response 
(ASR), may provide a better model for drug-induced psychosis or 
even idiopathic schizophrenia (Braff et al., 2001). PPI refers to the 
phenomenon of a reduction in the startle magnitude when the 
startling stimulus is preceded by a low-intensity prepulse. It has 
been widely used as a translational model of schizophrenia (Geyer 
and Braff, 1987; Swerdlow et al., 2008) which measures the sen-
sorimotor gating ability, a pre-attentive information processing 
mechanism that is putatively disrupted in patients with schizo-
phrenia and is thought to contribute to their sensory flooding 
and cognitive fragmentation (Braff and Geyer, 1990; Swerdlow et 
al., 2000). Animals treated with acute amphetamine, quinpirole 
(a D2/3 agonist), PCP or MK-801 (a NMDA antagonist) also ex-
hibit PPI deficits (Culm and Hammer, 2004; Mansbach and Geyer, 
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Prepulse inhibition (PPI) of acoustic startle response is impaired in patients with schizophrenia and in animals acutely 
treated with dopamine agonists and NMDA antagonists. In this study, we investigated the time course of PPI disruption 
induced by repeated amphetamine, quinpirole, phencyclidine (PCP), and dizocilpine (MK-801) treatment. We focused 
on how PPI disruption development was influenced by drug administration regimens, comparing a constant versus an es-
calating dosing regimen. Male Sprague–Dawley rats were repeatedly treated with amphetamine (1.25–5.0 mg/kg, or con-
stant 5.0 mg/kg, sc), PCP (0.50–2.0 mg/kg, or constant 0.5, 1.0 or 2.0 mg/kg, sc), quinpirole (0.03–0.12 mg/kg, or constant 
0.12 mg/kg, sc), MK-801 (0.025–0.10 mg/kg, or constant 0.10 mg/kg, sc) or vehicle (saline) and tested for PPI once daily 
for 6 consecutive days. When amphetamine 5.0 mg/kg or quinpirole 0.12 mg/kg was administrated on a constant dos-
ing schedule, both drugs disrupted PPI upon acute administration, but had no effect after repeated treatment and testing 
(days 2–5). However, when amphetamine 5.0 mg/kg or quinpirole 0.12 mg/kg was preceded by two lower doses in an esca-
lating dosing regimen, both drugs still disrupted PPI on days 5 and 6 when the constant amphetamine and quinpirole had 
no effect. For PCP and MK-801, repeated treatment under both regimens produced a stable and persistent disruption of 
PPI. Startle magnitude increased progressively and dose-dependently under both regimens for all drugs except for quin-
pirole, which caused a decrease. These results suggest that the drug dosing schedule, rather than the absolute amount of 
drug that an animal receives, has a greater impact on the development of PPI-disruptive effect of dopamine agonists than 
NMDA antagonists. Thus, in order to mimic the emerging process of PPI deficit with dopamine agonists, an escalating 
dosing regimen should be used.
Keywords: prepulse inhibition of acoustic startle, repeated amphetamine treatment, repeated phencyclidine treatment, 
quinpirole, dizocilpine (MK-801), sensitization effect, tolerance effect
509
510 Li,  He, & Chen in Pharmacology Biochemistry and Behavior 99 (2011) 
1989; Mansbach et al., 1988; Schwabe et al., 2005). However, it is 
not clear whether repeated treatment with these drugs induces a 
persistent disruption of PPI. So far, the evidence is inconclusive 
(Geyer et al., 2001). Sensitization (a progressive increase in PPI-
disruption), tolerance (a progressive decrease in PPI-disruption), 
and no change in PPI have all been reported (Culm and Hammer, 
2004; Mansbach et al., 1988; Martin-Iverson, 1999; Schulz et al., 
2001; Schwabe et al., 2005).
The paradigm used to administer psychotomimetic drugs is 
an extremely important variable to consider in evaluating drug-
induced behavioral sensitization phenomena (Fletcher et al., 
2005; Robinson and Becker, 1986; Tenn et al., 2005). The above-
mentioned conflicting reports may be due to differences in the 
treatment paradigms used, including drug doses, number of 
drug administrations, routes and treatment schedule, as well 
as the PPI testing schedule. In the present study, we sought to 
explore under what condition repeated treatment of amphet-
amine, quinpirole, PCP and MK-801 could produce a persistent 
disruption of PPI. We examined two dosing regimens. After ha-
bituation and baseline saline PPI tests were conducted, rats were 
treated under either a constant dosing regimen or an escalating 
dosing regimen for 6 consecutive days and their PPIs were tested 
daily. For amphetamine and quinpirole, we found that the con-
stant dosing regimen produced an acute disruption of PPI. But 
with repeated treatment and testing, both drugs no longer dis-
rupted PPI. In contrast, amphetamine and quinpirole adminis-
trated in an escalating dosing regimen produced PPI disruption 
even after repeated treatment and testing. For PCP and MK-
801, both treatment regimens produced a stable and persistent 
disruption of PPI at the dose range tested in this study (0.50–
2.0 mg/kg for PCP and 0.025–0.10 mg/kg for MK-801). Our re-
sults thus emphasize the importance of drug administration par-
adigms for different psychotomimetic drugs, rather than the 
amount of drugs, in producing different patterns of psychophar-
macological effects on PPI. They also suggest that for dopamine 
agonists or indirect agonists, an escalating dosing regimen may 
be more appropriate in inducing behavioral changes in rats with 
close resemblance to symptoms of schizophrenia.
2. Materials and methods
2.1. Animals
Male Sprague–Dawley rats (250–275 g upon arrival, 
Charles River, Portage, MI) were housed two per cage, in 
48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages 
under 12-h light/dark conditions (light on between 6:00 am and 
6:00 pm). Room temperature was maintained at 22° ± 1° with a 
relative humidity of 40–60%. Food and water was available ad li-
bitum. Animals were allowed at least 1 week of habituation to the 
animal facility before being used in experiments. All procedures 
were approved by the animal care committee at the University of 
Nebraska-Lincoln.
2.2. Prepulse inhibition of acoustic startle reflex apparatus
The prepulse inhibition test was performed using six Startle 
Monitor Systems (Kinder Scientific, Julian, CA). Each system, 
controlled by a PC, was housed in a compact sound attenuation 
cabinet (36 cm wide × 28 cm deep × 50 cm high). A speaker (di-
ameter: 11 cm) mounted on the cabinet’s ceiling was used to gen-
erate acoustic stimuli (70 dB–120 dB). The startle response was 
measured by a piezoelectric sensing platform on the floor, which 
was calibrated daily. During testing, rats were placed in a rect-
angular box made of transparent Plexiglas (19 cm wide × 9.8 cm 
deep × 14.6 high) with an adjustable ceiling positioned atop 
the box, providing only limited restraint while prohibiting 
ambulation.
2.3. Drugs
The injection solutions of d-amphetamine sulfate (AMPH, Sigma-
Aldrich, St. Louis, MO), quinpirole (QUI, Sigma-Aldrich, St. Louis, 
MO), (+)-MK-801 Hydrogen Maleate (a gift from NIMH Chemi-
cal Synthesis and Drug Supply Program) and PCP hydrochloride 
(a gift from NIDA Chemical Synthesis and Drug Supply Program) 
were obtained by mixing drugs with 0.9% saline. All injections 
were administrated subcutaneously at a volume of 1 ml/kg.
2.4. Experiment 1: Effects of repeated amphetamine (1.25–
5.0) or PCP (0.5–2.0) treatment on an escalating dose regi-
men or a constant dose regimen on prepulse inhibition
The entire experiment consisted of the following three phases, 
each separated by 1 day.
2.4.1. Phase 1: Handling and PPI habituation (2 days)
Rats (n = 60) were first handled individually for 2 days for ap-
proximately 2 min each day to minimize stress during behavioral 
testing. On the first handling day, the rats were acclimated to the 
prepulse inhibition apparatus for 10 min. On the second han-
dling day, the rats were also habituated to the PPI test procedure, 
which was adapted from Culm and Hammer (2004). The PPI ses-
sion lasted approximately 18 min and began with a 5 minute pe-
riod of 70 dB background noise (which continued throughout 
the duration of the session) followed by four different trial types: 
PULSE ALONE trials and three types of PREPULSE + PULSE tri-
als, which consisted of a 20 ms 73, 76, or 82 dB prepulse (3, 6, and 
12 dB above background) followed 100 ms later by a 120 dB pulse. 
Each session was divided into 4 blocks. Blocks 1 and 4 were iden-
tical, each consisting of 4 PULSE ALONE trials. Blocks 2 and 3 
were also identical and each consisted of 8 PULSE ALONE tri-
als and 5 of each PREPULSE + PULSE trial type. A total of 54 
trials were presented during each test session. Trials within each 
block were presented in a pseudorandom order and were sepa-
rated by a variable inter-trial interval averaging 15 s (ranging 
from 9 to 21 s). Startle magnitude was defined as the maximum 
force (measured in Newtons) applied by the rat to the startle ap-
paratus recorded over a period of 100 ms beginning at the on-
set of the pulse stimulus. Startle responses from testing blocks 2 
and 3 were used to calculate percent prepulse inhibition (%PPI) 
for each acoustic prepulse trial type:
%PPI = 100 –
 [(average startle response to PREPULSE + PULSE trials ) × 100]                               average startle response to PULSE ALONE trials        
 
2.4.2. Phase 2: PPI testing under vehicle (1 day)
One day after the second habituation day, rats were injected sub-
cutaneously with saline and tested for PPI 10 min after injection. 
The averaged %PPI at three prepulse levels (73, 76, and 82 dB) on 
this day was used to create matched groups such that all groups 
had comparable baseline PPI performance before the drug tests.
2.4.3. Phase 3: Repeated PPI testing under drug (6 days)
Five groups (n = 12/group) were formed on the basis of their PPI 
on the saline day: VEH (saline, sc), AMPH-constant (5.0 mg/
kg, sc), AMPH-escalating (1.25–5.0 mg/kg, sc), PCP-constant 
(2.0 mg/kg, sc), PCP-escalating (0.5–2.0 mg/kg, sc). During each 
daily test, rats were injected with either saline, AMPH or PCP 
10 min prior to being placed into the PPI boxes. Table 1 depicts 
the daily injection schedule.
2.5. Experiment 2: Effects of repeated PCP (0.5 or 1.0 mg/kg) 
treatment on a constant dose regimen on prepulse inhibition
Results from Experiment 1 showed that PCP (2.0 mg/kg) ad-
ministrated under the constant dosing schedule maintained its 
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disruption. Experiment 2 further examined this issue using two 
lower doses of PCP (0.5 and 1.0 mg/kg) and also addressed the po-
tential floor effect (PCP at 2.0 mg/kg already caused a maximal 
PPI disruption, leaving no room to show a sensitization effect). 
Two lower doses of PCP (0.5 and 1.0 mg/kg) were used. The basic 
procedure was identical to that of Experiment 1. Based on the PPI 
performance on the saline day, 36 rats were matched and assigned 
to three groups (n = 12/group): VEH (saline), PCP 0.5 mg/kg and 
PCP 1.0 mg/kg, and their PPIs were tested for 6 days.
2.6. Experiment 3: Effects of repeated quinpirole (0.03–0.12) 
or MK-801 (0.025–0.1) treatment on an escalating dose regi-
men or a constant dose regimen on prepulse inhibition
Quinpirole and MK-801 are two drugs that are often used in the 
study of animal models of schizophrenia. Like amphetamine and 
PCP, both drugs affect dopamine and NMDA-mediated neuro-
transmission and acutely disrupt PPI, but their repeated effects on 
PPI are less clear. This experiment investigated the effects of re-
peated administration of quinpirole and MK-801 under the two 
dosing schedules on PPI. We were interested in whether the reg-
imen effect with amphetamine and PCP could also be found 
with quinpirole and MK-801. The basic procedure was identical 
to that of Experiment 1. Sixty rats were matched and assigned to 
five groups (n = 12/group): VEH (saline), QUI-constant (0.12 mg/
kg, sc), QUI-escalating (0.03–0.12 mg/kg, sc), MK-801-constant 
(0.10 mg/kg, sc), MK-801-escalating (0.025–0.10 mg/kg, sc). PPI 
was tested for 6 days. During each daily test, rats were injected 
with either saline or one of the drugs 10 min prior to being placed 
into the PPI boxes. Table 2 depicts the daily injection schedule.
2.7. Statistical analysis
Percent PPI data for the 6 drug days were presented separately 
for three prepulse intensities (e.g. 73, 76 and 82 dB). The magni-
tude of the acoustic startle reflex (ASR) was calculated as the av-
erage response on the PULSE ALONE trials, excluding the first 
and last blocks of 4 PULSE ALONE trials. Percent PPI and ASR 
data from the drug test period were first analyzed using SPSS 
(v19) repeated measures ANOVAs with drug treatment (i.e. ve-
hicle, constant or escalating) as a between-subjects factor and 
test day (i.e. 6) as a within-subjects factor. For PPI data, another 
within-subjects factor (i.e. 3 prepulse levels) was also included 
in the analysis. If necessary, one-way ANOVAs followed by post 
hoc LSD tests were used to identify between-group differences 
on specific days, and paired-samples t tests were used to iden-
tify the temporal changes of treatment effects from day 1 to day 
6. Data for each drug (e.g. AMPH and PCP) were analyzed sep-
arately because we were primarily interested in the effects of 
 
 
 
 
 
 
 
 
 
 
dosing regimen and less interested in differences between drugs. 
For all analyses, P < 0.05 was considered statistically significant.
3. Results
3.1. Experiment 1: Effects of repeated amphetamine (1.25–
5.0) or PCP (0.5–2.0) treatment on an escalating dose regi-
men or a constant dose regimen on prepulse inhibition
Due to equipment malfunction on the last drug test day, data 
for 12 rats were lost (1 vehicle, 3 AMPH-constant, 3 AMPH-es-
calating, 2 PCP-constant and 3 PCP-escalating rats). The follow-
ing analysis was based on the data from the remaining 48 rats 
(n = 9–11/group).
3.1.1. PPI
As expected, there was no group difference on the averaged per-
cent PPI on the saline day (F(4, 55) = 0.08, P = 0.988, data not 
shown). For amphetamine, analysis of PPI data from the 6 drug 
test days revealed a main effect of treatment (F(2, 26) = 4.249, 
P = 0.025), prepulse level (F(2, 52) = 366.66, P < 0.001) and a 
significant treatment × test day interaction (F(10, 130) = 3.472, 
P < 0.001). These results suggest that amphetamine disrupted 
PPI and the disruption varied in different treatment schedules 
and across the test days.
At all three prepulse intensity levels (Figure 1A, B and C), 
one-way ANOVA followed by LSD post hoc tests revealed that 
the AMPH-constant group had significantly lower PPIs than 
the other two groups only on day 1 (all Ps < 0.003), indicating 
an acute PPI-disruptive effect of AMPH at 5.0 mg/kg. In con-
trast, the AMPH-escalating group had significantly lower PPIs 
than the vehicle group primarily on day 5 and 6 at the 76 dB 
(P = 0.014, and 0.050) and 82 dB levels (P = 0.009 and 0.008). It 
also had a significantly lower PPI than the vehicle group at the 
76 dB level on day 1 (P = 0.011).
When PPIs on day 6 of drug testing were compared to those on 
day 1, the vehicle and AMPH-escalating groups did not show any 
significant change in PPI at all three prepulse levels (all Ps > 0.105). 
In contrast, the AMPH-constant group had significantly higher 
PPIs on day 6 than on day 1 at the 73 dB (P = 0.007) and 82 dB lev-
els (P = 0.033), indicating that repeated AMPH treatment at this 
constant dose induced a tolerance-like effect on PPI disruption.
For PCP, repeated measures ANOVA showed a main ef-
fect of treatment (F(2, 27) = 54.987, P < 0.001) and prepulse 
level (F(2, 54) = 359.939, P < 0.001). There was also a significant 
treatment × test day interaction (F(10, 135) = 1.932, P = 0.046), 
and a significant treatment × prepulse level interaction (F(4, 
54) = 11.211, P < 0.001). These results suggest that the disruptive 
effect of PCP on PPI varied under different treatment schedules 
and differed at different prepulse levels on different test days.
At the 73 and 76 dB prepulse intensity levels (Figure 2A and 
B), one-way ANOVA followed by LSD post hoc tests revealed 
that both PCP groups had significantly lower PPIs than the vehi-
cle group on every test day (all Ps < 0.035) except on day 3 when 
the difference between the PCP-escalating group and the vehicle 
group did not reach the significant level (P = 0.059) at the 73 dB 
level. In addition, the PCP-constant group also had a significantly 
lower PPI than the PCP-escalating group on day 3 at the 73 dB pre-
pulse level (P = 0.010) and on day 4 at the 76 dB prepulse level 
(P = 0.011). Similarly, at the 82 dB prepulse intensity level (Fig-
ure 2C), both PCP groups had significantly lower PPIs than the 
vehicle group on all 6 test days (all Ps < 0.001). In addition, the 
PCP-constant group also had significantly lower PPIs than the 
PCP-escalating group on day 3 (P < 0.008) and day 4 (P < 0.044).
Comparing day 1 versus day 6, neither the PCP-constant nor 
the PCP-escalating group showed any significant change in PPI 
at all three prepulse levels (all Ps > 0.176), indicating that re-
peated PCP treatment under either treatment schedule pro-
duced a persistent PPI disruption.
Table 1. Groups and drug treatment for Experiment 1 (All drugs were ad-
ministrated subcutaneously at a volume of 1 ml/kg).
Group N D1 D2 D3 D4 D5 D6
Vehicle 12 SAL SAL SAL SAL SAL SAL
AMPH constant 12 5.0 5.0 5.0 5.0 5.0 5.0
AMPH escalating 12 1.25 1.25 2.5 2.5 5.0 5.0
PCP constant 12 2.0 2.0 2.0 2.0 2.0 2.0
PCP escalating 12 0.5 0.5 1.0 1.0 2.0 2.0
Table 2. Groups and drug treatment for Experiment 3 (All drugs were 
administrated subcutaneously at a volume of 1 ml/kg).
Group No. Drug treatment (Days 1–6)
Vehicle 12 SAL SAL SAL SAL SAL SAL
QUI constant 12 0.12 0.12 0.12 0.12 0.12 0.12
QUI escalating 12 0.03 0.03 0.06 0.06 0.12 0.12
MK-801 constant 12 0.10 0.10 0.10 0.10 0.10 0.10
MK-801 escalating 12 0.025 0.025 0.05 0.05 0.10 0.10
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3.1.2. Acoustic startle response (ASR)
For AMPH (Figure 3A), both AMPH regimens progressively 
enhanced startle amplitude over the treatment period. Re-
peated measures ANOVAs showed a main effect of test day (F(5, 
130) = 7.520, P < 0.001) and a significant treatment × test day in-
teraction (F(10, 130) = 5.049, P < 0.001). One-way ANOVAs fol-
lowed by LSD post hoc test on each test day showed that the 
AMPH-constant group had significantly higher startle ampli-
tude than the vehicle group on days 3, 4, 5 and 6 (all Ps < 0.043 
vs. vehicle) (Figure 3A). The AMPH-escalating group had sig-
nificantly higher startle amplitude than the vehicle group only 
on day 5 (P = 0.010). For PCP (Figure 3B), repeated measures 
ANOVAs showed a main effect of treatment (F(2, 27) = 5.737, 
P = 0.008) and a significant treatment × test day interaction 
(F(10, 135) = 2.364, P = 0.013). One-way ANOVAs showed that 
both PCP groups significantly enhanced startle amplitude on all 
6 test days (all Ps < 0.043 vs. vehicle) with the exception of the 
PCP-constant group on day 1 (P = 0.154).
Figure 1. Effects of repeated administration of saline (VEH), constant 
amphetamine (5.0 mg/kg daily), or escalating amphetamine (1.25–
5.0 mg/kg) for 6 consecutive days on prepulse inhibition (PPI) at the 
73 dB (A), 76 dB (B), and 82 dB (C) prepulse levels. * P < 0.05 signifi-
cantly different from the VEH group; # P < 0.05 significantly different 
between the two amphetamine groups; $ P < 0.05 significantly different 
between day 1 and day 6.
Figure 2. Effects of repeated administration of saline (VEH), constant 
PCP (2.0 mg/kg daily), or escalating PCP (0.5–2.0 mg/kg) for 6 consec-
utive days on prepulse inhibition (PPI) at the 73 dB (A), 76 dB (B) and 
82 dB (C) prepulse levels. * P < 0.05 significantly different from the VEH 
group; # P < 0.05 significantly different between the two PCP groups.
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3.2. Experiment 2: Effects of repeated PCP (0.5 or 1.0 mg/
kg) treatment on a constant dose regimen on prepulse 
inhibition
Due to equipment malfunction on the 5th drug test day, data for 
4 rats were lost (2 vehicle rats and 2 PCP 0.5 mg/kg rats). The 
following analysis was based on the data from the remaining 32 
rats (n = 10–12/group).
3.2.1. PPI
As expected, there was no group difference on the averaged percent 
PPI on the saline day (F(2, 33) = 0.074, P = 0.929). Analysis of PPI 
data from the 6 drug test days revealed a main effect of treatment 
(F(2, 29) = 11.853, P < 0.001) and prepulse level (F(2, 58) = 328.635, 
P < 0.001), but no main effect of test day (F(5, 145) = 0.832, 
P = 0.529), nor a significant treatment × test day interaction (F(10, 
145) = 1.70, P = 0.086). In addition, the treatment × prepulse level 
interaction was also not significant (F(4, 58) = 2.518, P = 0.051). 
Like the effect of PCP administered in the constant dosing regimen 
seen in Experiment 1, PCP at 0.5 and 1.0 mg/kg produced a persis-
tent disruption of PPI across the test days.
At the 73 dB prepulse intensity level (Figure 4A), one-way 
ANOVA followed by LSD post hoc tests revealed that the PCP 
1.0 group had significantly lower PPIs than the vehicle group 
 
 
 
 
 
 
 
 
 
 
 
 
on day 1 (P = 0.009) and day 5 (P = 0.036), whereas the PCP 0.5 
group had significantly lower PPI only on day 6 (P = 0.020). At 
the 76 dB prepulse intensity level (Figure 4B), both PCP groups 
had significantly lower PPIs than the vehicle group on every test 
day (all Ps < 0.036) except on day 5 when the difference between 
the PCP 0.5 and vehicle group was only marginally significant 
(P = 0.051). At the 82 dB prepulse intensity level (Figure 4B), the 
PCP 1.0 group had significantly lower PPIs than the vehicle group 
on every test day (all Ps < 0.048), whereas the PCP 0.5 group had 
significantly lower PPIs on days 1, 3, and 4 (all Ps < 0.042).
The vehicle and PCP 1.0 groups did not show any significant 
change in PPI performance at all three prepulse levels from day 1 
to day 6 (all Ps > 0.713). The only significant change noticed was in 
Figure 3. Effects of repeated administration of saline (VEH), constant 
amphetamine (5.0 mg/kg daily), escalating amphetamine (1.25–5.0 mg/
kg) (A), constant PCP (2.0 mg/kg daily), or escalating PCP (0.5–2.0 mg/
kg) for 6 consecutive days (B) on startle reactivity (e.g. startle responses 
on 120 dB white noise trials). Startle magnitude (mean ± SEM) was cal-
culated as the average response on the PULSE ALONE trials, excluding 
the first and last block of 4 PULSE ALONE trials. * P < 0.05 significantly 
different from the VEH group.
Figure 4. Effects of repeated administration of saline (VEH), PCP 
(0.5 mg/kg) or PCP (1.0 mg/kg) daily for 6 consecutive days on prepulse 
inhibition (PPI) at the 73 dB (A), 76 dB (B) and 82 dB (C) prepulse levels. 
* P < 0.05 significantly different from the VEH group; # P < 0.05 signifi-
cantly different between the two PCP groups.
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the PCP 0.5 group which had significantly lower PPI at the 73 dB 
level on day 6 than on day 1 (P = 0.026). Collectively, these data 
indicate that repeated PCP treatment under the constant dosing 
schedules produced a stable and persistent PPI disruption.
3.2.2. Acoustic startle response (ASR)
There was a main effect of test day (F(5, 145) = 3.982, P = 0.002), 
but no main effect of PCP (F(2,29) = 0.288, P = 0.752), or 
PCP × test day interaction (F(10,145) = 1.251, P = 0.264). One-way 
ANOVAs did not find any group difference on any test day (all 
Ps > 0.453, Figure 5).
3.3. Experiment 3: Effects of repeated quinpirole (0.03–0.12) 
or MK-801 (0.025–0.1) treatment on an escalating dose regi-
men or a constant dose regimen on prepulse inhibition
3.3.1. PPI
As expected, there was no group difference on the averaged per-
cent PPI on the saline day (F(4, 55) = 0.085, P = 0.987, data not 
shown). Quinpirole at 0.12 mg/kg disrupted PPI acutely. Analysis 
of PPI data from the 6 drug test days revealed a main effect of pre-
pulse level (F(2, 66) = 332.485, P < 0.001) and a significant treat-
ment × test day interaction (F(10, 165) = 2.177, P = 0.022), but no 
main effect of treatment (F(2, 33) = 2.424, P = 0.104). These results 
suggest that quinpirole disrupted PPI and that the disruption var-
ied in different treatment schedules and across the test days.
At the 73 dB prepulse level (Figure 6A), one-way ANOVA fol-
lowed by LSD post hoc tests revealed that the QUI-escalating 
group had significantly higher PPIs than the other two groups only 
on day 4 (all Ps < 0.031). At the 76 dB prepulse intensity level (Fig-
ure 6B), the QUI-constant group had a significantly lower PPI 
than the vehicle group (P = 0.008) on day 1, indicating an acute 
disruptive effect. It also had significantly lower PPIs than the QUI-
escalating group on day 1 (P = 0.032), day 3 (P = 0.023) and day 
4 (P = 0.037). Interestingly, the QUI-escalating group had a sig-
nificantly higher PPI than the vehicle group on day 4 (P = 0.011). 
At the 82 dB prepulse intensity level (Figure 6C), the QUI-con-
stant group had a significantly lower PPI than the vehicle group 
(P = 0.043) on day 1. It also had significantly lower PPIs than the 
QUI-escalating group on day 1 (P = 0.030), day 2 (P = 0.013), day 
3 (P = 0.038) and day 4 (P = 0.015). The QUI-escalating group had 
a significantly lower PPI than the vehicle group on the last day of 
testing (P = 0.038), when the same dose of QUI in the constant 
schedule had no effect (P = 0.146).
In comparison to day 1 of drug testing, only the QUI-escalat-
ing group showed a significantly increased disruption of PPI at 
the 82 dB level on day 6 (P = 0.035). None of the other groups 
showed any significant change (all Ps > 0.065).
For MK-801, repeated measures ANOVA showed a main ef-
fect of treatment (F(2, 33) = 17.848, P < 0.001) and prepulse level 
(F(2, 66) = 360.912, P < 0.001). There was also a significant treat-
ment × test day interaction (F(10, 165) = 2.605, P = 0.006). These 
Figure 5. Effects of repeated administration of saline (VEH), PCP (0.5 mg/
kg), or PCP (1.0 mg/kg) for 6 consecutive days on startle reactivity.
Figure 6. Effects of repeated administration of saline (VEH), constant 
quinpirole (0.12 mg/kg daily) or escalating quinpirole (0.03–0.12 mg/kg) 
for 6 consecutive days on prepulse inhibition (PPI) at the 73 dB (A), 76 dB 
(B) and 82 dB (C) prepulse levels. * P < 0.05 significantly different from the 
VEH group; # P < 0.05 significantly different between the two quinpirole 
groups; $ P < 0.05 significantly different between day 1 and day 6.
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results suggest that the disruptive effect of MK-801 on PPI var-
ied under different treatment schedules and differed across the 
six test days.
At the 73 dB prepulse intensity level (Figure 7A), one-way 
ANOVA followed by LSD post hoc tests revealed that the MK-
801-constant group had significantly lower PPIs than the ve-
hicle group on every test day (all Ps < 0.030) except on day 4 
(P = 0.058). In addition, the MK-801-constant group also had a 
significantly lower PPI than the MK-801-escalating group on day 
3 (P = 0.006). The MK-801-escalating group had significantly 
lower PPIs than the vehicle group on day 1 (P = 0.003) and day 
6 (P = 0.023). At the 76 dB prepulse level (Figure 7B), the MK-
801-constant group had significantly lower PPIs than the vehicle 
group on every test day (all Ps < 0.044), whereas the MK-801-es-
calating group had significantly lower PPIs on days 1, 2, 5 and 
6 (all Ps < 0.023). It also had a significantly lower PPI than the 
constant group on day 6 (P = 0.012). At the 82 dB prepulse in-
tensity level (Figure 7C), the MK-801-constant group had signif-
icantly lower PPIs than the vehicle group on every test day (all 
Ps < 0.006). It also had a significantly lower PPI than the escalat-
ing group on day 3 (P = 0.042). The MK-801-escalating group had 
significantly lower PPIs than the vehicle group on days 2, 4, 5 and 
6 (all Ps < 0.032), and significantly lower PPIs than the constant 
group on days 5 and 6 (Ps < 0.038).
In comparison to day 1 of drug testing, only the MK-801-esca-
lating group showed a significantly increased disruption of PPI 
at the 82 dB level on day 6 (P = 0.014). None of the other groups 
showed any significant change (all Ps > 0.060).
3.3.2. Acoustic startle response (ASR)
QUI treatment decreased startle reactivity (Figure 8A). Repeated 
measures ANOVAs showed a main effect of treatment (F(2, 
33) = 5.366, P = 0.010), a main effect of test day (F(5, 165) = 4.141, 
P = 0.001) and a significant treatment × test day interaction 
(F(10, 165) = 3.633, P < 0.001). One-way ANOVAs followed by 
LSD post hoc test on each test day showed that the QUI-con-
stant group had significantly lower startle amplitude than the 
vehicle group on every test day (all Ps < 0.047). The QUI-escalat-
ing group had significantly lower startle amplitude than the ve-
hicle group on days 2, 3, 5 and 6 (all Ps < 0.035).
MK-801 treatment increased startle reactivity (Figure 8B). 
Repeated measures ANOVAs showed a main effect of treat-
ment (F(2, 33) = 8.527, P = 0.001), a main effect of test day (F(5, 
165) = 10.538, P < 0.001) and a significant treatment × test day in-
teraction (F(10, 165) = 8.523, P < 0.001). One-way ANOVAs fol-
lowed by LSD post hoc test on each test day showed that both 
MK-801 groups had significantly higher startle amplitude than 
the vehicle group on every test day (all Ps < 0.031) except on day 
2 when the MK-801-escalating group did not differ significantly 
from the vehicle group (P = 0.368).
4. Discussion
Previous work on the effects of repeated administration of dopa-
mine agonists and NMDA antagonists on PPI has reported either 
no change (Druhan et al., 1998; Mansbach et al., 1988; Martinez 
et al., 1999; Schwabe et al., 2005), sensitization (Martin-Iverson, 
1999; Schulz et al., 2001; Zhang et al., 1998), or tolerance in PPI 
(Culm and Hammer, 2004; Feifel et al., 2002) (see (Geyer et al., 
2001; Swerdlow et al., 2008) for detailed tabulations). Besides the 
parameter differences in PPI testing, we hypothesized that some 
of these differences may be attributable to differences in drug 
treatment paradigms, including drug doses, number of drug ad-
ministrations, routes and treatment schedule, etc. The present 
study confirmed this hypothesis regarding dopamine agonists. 
For the first time, we showed that when amphetamine 5.0 mg/kg 
or quinpirole 0.12 mg/kg was administered in an escalating dos-
ing regimen, both drugs still caused a disruption of PPI on the 
test days (days 5 and 6) when the same dose of amphetamine or 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
quinpirole in the constant dosing schedule already lost its effect. 
We recently confirmed this general observation in a subsequent 
experiment using different doses of amphetamine in the two 
schedules. We found that rats that received an escalating am-
phetamine treatment (days 1–2: 1.0 mg/kg; days 3–4: 2.0 mg/kg, 
and days 5–6: 4.0 mg/kg) exhibited PPI deficits on the last 2 days 
when they were tested under 4.0 mg/kg amphetamine. However, 
this same dose of amphetamine did not disrupt PPI on the last 
2 days when it was administered in the constant schedule (days 
1–6: 4.0 mg/kg). The consistence of the findings involving differ-
ent doses of amphetamine suggests the generality of such treat-
ment regimen effect on PPI change.
Figure 7. Effects of repeated administration of saline (VEH), constant 
MK-801 (0.1 mg/kg daily) or escalating MK-801 (0.025–0.10 mg/kg) for 6 
consecutive days on prepulse inhibition (PPI) at the 73 dB (A), 76 dB (B) 
and 82 dB (C) prepulse levels. * P < 0.05 significantly different from the 
VEH group; # P < 0.05 significantly different between the two quinpirole 
groups; $ P < 0.05 significantly different between day 1 and day 6.
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The constant dosing of amphetamine and quinpirole tended 
to produce a progressively decreased disruption on PPI (a tol-
erance-like effect). This finding is consistent with earlier stud-
ies demonstrating the similar tolerance development associated 
with repeated cocaine, amphetamine, quinpirole or apomorphine 
treatment (Byrnes and Hammer, 2000; Druhan et al., 1998; Feifel 
et al., 2002; Martin-Iverson, 1999). Interestingly, in contrast to the 
varying effects of different treatment schedules on PPI, amphet-
amine or quinpirole administered in both conditions induced a 
similar enhanced (a sensitization-like effect for amphetamine) 
or decreased (for quinpirole) effect on startle reactivity through-
out the treatment days (Figures 3A and 8A), suggesting a dissoci-
ation between their PPI effects and effects on startle reactivity, as 
they did not occur in parallel. For example, amphetamine 5.0 mg/
kg in the constant dosing schedule caused a significant increase 
in startle magnitude on day 6, but it did not disrupt PPI. Con-
versely, amphetamine 5.0 mg/kg in the escalating dosing sched-
ule did not change startle magnitude on day 6, but it did disrupt 
PPI. A similar case could be made for quinpirole. These observa-
tions also suggest that the PPI tolerance effect of amphetamine 
was not due to a loss of drug action over time, but rather due to 
the specific sensitivity of PPI to this drug action. Furthermore, as 
rats in the constant dosing groups actually received more amphet-
amine or quinpirole, these results suggest that the drug dosing 
schedule, rather than the absolute amount of drug that an animal 
receives plays an important role in the development of PPI-dis-
ruptive effect of amphetamine or quinpirole. It suggests that the 
brain mechanisms underlying amphetamine-induced change in 
PPI disruption may be different from those underlying its sensi-
tization effect on psychomotor function (Druhan et al., 1998). The 
dissociation between AMPH-induced PPI disruption and psycho-
motor sensitization implies that sensitization-like processes and 
associated neuroadaptation may not be crucial in the develop-
ment of a sensorimotor gating deficit as observed in patients with 
schizophrenia, although it is required for behavioral sensitization 
(Robinson and Becker, 1986).
Our finding that repeated treatment of PCP and MK-801 un-
der the constant and escalating regimens at the tested dose 
ranges produced a stable and persistent disruption of PPI is con-
sistent with Martinez et al. (1999) and Schwabe et al. (2005). It is 
inconsistent with Schulz et al. (2001), who tested MK-801 in Wis-
tar rats. Thus, this discrepancy could be due to strain-differences 
between Wistar and Sprague–Dawley rats (Varty and Higgins, 
1995), as the latter is more sensitive to the disruptive effect of 
NMDA antagonists. One may suggest that the failure to detect a 
sensitization effect might be due to a floor effect in the sense that 
PCP and MK-801 at the chosen doses already achieved a maxi-
mal PPI disruption. However, the finding that PCP at a low dose 
(i.e. 0.5 mg/kg) still failed to induce a consistent increased dis-
ruption of PPI (Figure 4) argues against the floor effect explana-
tion. Overall, our results suggest that the PPI disruption induced 
by PCP and MK-801 (at the effective dose) is generally quite sta-
ble. One caveat is that we only tested relatively low doses of PCP 
and MK-801 (< 2.0 mg/kg for PCP and < 0.1 mg/kg for MK-801) 
in this study. Other doses of PCP and MK-801 may induce dif-
ferent patterns of PPI disruption under different experimental 
conditions.
To the best of our knowledge, there is no published work 
that has examined the effects of escalating dose regimen on 
PPI throughout the course of drug treatment. Several studies 
that have used escalating dosing regimens only tested PPI after 
a period of withdrawal from a repeated treatment of amphet-
amine or PCP. Results are inconsistent. For example, Murphy et 
al. (2001a, 2001b) and Russig et al. (2003) reported no PPI dis-
ruption in rats treated with an escalating dose of amphetamine, 
whereas Tenn et al. (2003, 2005) reported a disruption of PPI in 
rats treated with an escalating dose of amphetamine, but not in 
rats treated with the same doses of PCP over the same period of 
time. Peleg-Raibstein et al. (2006) found that prior AMPH treat-
ment schedule is a critical factor in inducing a long-lasting dis-
ruption of PPI. Clinical observations indicate that drug-induced 
psychosis is most likely to appear during the course of escalat-
ing dosage of drug administration (i.e., “binges” or “runs”), and 
discontinuation of drug usage usually results in a rapid de-
cline of the psychosis, closely paralleling urine drug levels (An-
grist, 1994; Davis and Schlemmer, 1980). Our finding that an es-
calating dose of amphetamine produces a sustained disruption 
in drug experienced rats seems to capture the emergence of one 
important psychological dysfunction (e.g. sensorimotor gating) 
identified in patients with schizophrenia very well. This study 
thus provides two important paradigms for basic researchers 
who are interested in developing animal models that can mimic 
the emerging process of sensorimotor gating deficits in patients 
with schizophrenia. One option is to use an escalating dosing 
regimen with dopamine agonists. The second is to use effective 
and low doses of NMDA antagonists such as PCP or MK-801. PPI 
disruption induced and maintained under these conditions may 
therefore allow us to dissect the neural and neurochemical basis 
of symptoms of schizophrenia.
The present study raised an interesting question: Why is an 
escalating dosing regimen with amphetamine or quinpirole able 
to induce PPI disruption when the same dose of drugs in the 
constant schedule is no longer effective? Neurochemical stud-
ies have showed that during the course of escalating dose treat-
ment, extracellular dopamine and serotonin levels in the dorsal 
and ventral striatum progressively declined (Segal and Kuczen-
ski, 1997), and striatal dopamine release to a challenge amphet-
Figure 8. Effects of repeated administration of saline (VEH), quinpirole 
(0.12 mg/kg daily or 0.03–0.12 mg/kg escalating throughout 6 days) (A) or 
MK-801 (or 0.025–0.10 mg/kg escalating throughout 6 days) (B) on startle 
reactivity (e.g. startle responses on 120 dB white noise trials). * P < 0.05 
significantly different from the VEH group.
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amine dose or stress was significantly enhanced, whereas do-
pamine release remained significantly decreased in the dorsal 
medial prefrontal cortex (mPFC) after a certain period of with-
drawal (Hedou et al., 2001; Paulson and Robinson, 1995; Tenn et 
al., 2003). This suggests that complex, time-dependent neuroad-
aptations in dopamine systems may lead to persistent PPI dis-
ruption under the escalating schedule. Apparently, future work 
is needed to elucidate the exact neurochemical mechanisms.
Finally, we should point out that other factors may also in-
fluence a drug’s effect on PPI, in addition to the drug adminis-
tration regimen and PPI parameters. One such factor is whether 
drug treatment is paired with the PPI testing environment dur-
ing the repeated drug treatment period. Since repeated PPI test-
ing involves repeated presentation of startle stimulus which is 
a mild stressor by itself, repeated daily testing could conceiv-
ably alter drug effects on PPI over time by altering the impacts of 
emotional responses (e.g. fear) on PPI performance. In the liter-
ature, a tolerance-like or sensitization-like disruption on PPI has 
often been found under a condition when the drug injections 
were paired with repeated PPI testing (Culm et al., 2004; Feifel 
et al., 2002; Martin-Iverson, 1999; Schulz et al., 2001; Zhang et 
al., 1998), whereas repeated drug treatment that was not paired 
with PPI testing did not result in PPI change (Byrnes and Ham-
mer, 2000; Druhan et al., 1998; Mansbach et al., 1988; Martinez 
et al., 1999). It has therefore been suggested that repeated ef-
fects of drug treatment on PPI-disruption might be revealed only 
in the presence of a drug-associated context (Feifel et al., 2002; 
Martin-Iverson, 1999; Russig et al., 2003). Our findings with am-
phetamine and quinpirole are consistent with this explanation. 
This idea fits well with the proposition that psychomotor sensiti-
zation is context-specific, and under certain conditions, psycho-
motor sensitization can only be detected in a specific environ-
ment where repeated drug administration occurs (Anagnostaras 
and Robinson, 1996; Robinson and Becker, 1986). However, the 
impact of this factor may be limited to dopamine agonists be-
cause we did not observe any change with NMDA antagonists 
(e.g. PCP and MK-801). In light of the evidence that drug-envi-
ronment pairing is important for the induction of psychomotor 
sensitization for dopamine agonists (Anagnostaras and Robin-
son, 1996), the lack of impact of such a factor on amphetamine-
induced PPI change further suggests that the neural basis re-
sponsible for amphetamine-induced change in PPI disruption is 
likely different from those underlying its psychomotor sensitiza-
tion (Druhan et al., 1998). Future work should address this issue 
further by examining how this factor interacts with other factors 
(e.g. PPI testing parameters and drug dosing regimens) in deter-
mining the PPI-disruptive effect. This approach will enhance our 
ability to develop more reliable animal models based on phar-
macological treatment.
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